AJANTPHARM.NS实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (6 May 2024 @ 18:00):

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages...

Stats
今日成交量	364 632
平均成交量	161 866
市值	304.03B
EPS	INR0 ( 2024-05-01 )
下一个收益日期	( INR23.80 ) 2024-07-24
Last Dividend	INR15.00 ( 2023-08-04 )
Next Dividend	INR0 ( N/A )
P/E	41.44
ATR14	INR2.32 (0.10%)

音量相关性

長: -0.01 (neutral)

短: -0.26 (neutral)

Signal:(52.563) Neutral

Ajanta Pharma Limited 相关性

10 最正相关
BHARATWIRE.NS	0.837
IZMO.NS	0.823
ASHIANA.NS	0.821
ASIANHOTNR.NS	0.805
AUROPHARMA.NS	0.801
GISOLUTION.NS	0.801

10 最负相关
STARTECK.NS	-0.829
SEYAIND.NS	-0.806

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ajanta Pharma Limited 相关性 - 货币/商品

0.17
( neutral )

0.03
( neutral )

0.07
( neutral )

0.55
( weak )

-0.13
( neutral )

Ajanta Pharma Limited 财务报表

Annual	2023
营收:	INR42.09B
毛利润:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2023
营收:	INR42.09B
毛利润:	INR21.06B (50.05 %)
EPS:	INR64.82

FY	2022
营收:	INR37.43B
毛利润:	INR26.92B (71.93 %)
EPS:	INR45.89

FY	2022
营收:	INR32.84B
毛利润:	INR23.97B (73.00 %)
EPS:	INR54.97

Financial Reports:

No articles found.

Ajanta Pharma Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR7.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR15.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ajanta Pharma Limited Dividend Information - Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 5.30 - Stable (6.10%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.133	2002-12-17
Last Dividend	INR15.00	2023-08-04
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	20	--
Total Paid Out	INR73.42	--
Avg. Dividend % Per Year	0.57%	--
Score	3.24	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	5.30
Div. Directional Score	7.71	--

Next Divdend (Est)
(2024-08-29)

INR16.81 Estimate 3.06 %

Dividend Stability

0.24 Very Poor

Dividend Score

3.24

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR6.00	0.78%
2019	INR8.67	1.10%
2020	INR6.33	0.97%
2021	INR6.33	0.58%
2022	INR7.00	0.47%
2023	INR15.00	1.24%
2024	INR0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
STEELCAS.NS	Dividend Knight	2023-08-14	Bi-Monthly	3	0.88%
MURUDCERA.NS	Dividend Junior	2023-09-14	Sporadic	21	0.33%
HINDCOPPER.NS	Dividend Junior	2023-09-22	Sporadic	15	0.47%
BPCL.NS	Dividend Knight	2023-08-11	Semi-Annually	29	3.25%
RELIANCE.NS	Dividend Knight	2023-08-21	Annually	29	0.24%
KRITINUT.NS	Dividend Junior	2023-08-21	Insufficient data to determine frequency	2	0.17%
FIEMIND.NS	Dividend Knight	2023-07-20	Semi-Annually	18	2.12%
ANDHRSUGAR.NS	Dividend Junior	2023-09-14	Annually	23	1.54%
TATACONSUM.NS	Dividend Junior	2023-05-19	Annually	26	0.60%
NIPPOBATRY.NS	Dividend Junior	2023-09-20	Annually	23	1.06%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.194	1.500	6.12	9.18	[0 - 0.5]
returnOnAssetsTTM	0.176	1.200	4.13	4.96	[0 - 0.3]
returnOnEquityTTM	0.235	1.500	8.51	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	3.05	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	1.944	0.800	3.27	2.62	[0.8 - 2.5]
cashRatioTTM	0.146	1.500	-0.300	-0.450	[0.2 - 2]
debtRatioTTM	0.00761	-1.500	9.87	-10.00	[0 - 0.6]
interestCoverageTTM	147.56	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
freeCashFlowPerShareTTM	16.08	2.00	1.958	3.92	[0 - 20]
debtEquityRatioTTM	0.00989	-1.500	9.96	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.683	1.000	1.951	1.951	[0.2 - 0.8]
operatingProfitMarginTTM	0.253	1.000	6.94	6.94	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.74	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.907	0.800	7.28	5.83	[0.5 - 2]
Total Score				10.12

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	35.96	1.000	6.47	0	[1 - 100]
returnOnEquityTTM	0.235	2.50	9.04	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	16.08	2.00	4.64	3.92	[0 - 30]
dividendYielPercentageTTM	1.759	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	16.08	2.00	4.64	9.28	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.068	1.500	6.22	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0481	1.000	-1.297	0	[0.1 - 0.5]
Total Score				5.30

Ajanta Pharma Limited

Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets finished dosages. The company markets and serves various therapeutic segments, such as anti-biotic, anti-malarial, anti-diabetic, cardiology, gynecology, pediatric, respiratory and general health products, dermatology, ophthalmology, and pain management areas. It also provides multivitamins, antibiotics, eye drops, cough syrups, etc. The company serves in India, Africa, rest of Asia, the United States, and internationally. It supplies its products to government bodies, including armed forces, government hospitals, canteens, stores department, etc. The company was founded in 1973 and is headquartered in Mumbai, India.